Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-BCMA CAR-T Cell Therapy in R/R Multiple Myeloma
NCT07477912Phase 2Recruiting
- Sponsor
- Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
- Start
- Feb 2025
- Primary completion
- Feb 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of anti-BCMA CAR-T cells in multiple myeloma (MM), sponsored by Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology. Started Feb 2025; status: recruiting.
02
Drugs
anti-BCMA CAR-T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07477912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07477912.